4 February 2023 in General Reanimatology
Materials and methods. This study analyzed the results of treatment of 62 patients with severe COVID-19 in the intensive care unit using selective hemoadsorption of cytokines. All patients with severe COVID-19 were admitted to the intensive care unit within 14 days from the disease onset were subdivided into two groups. Group 1 patients (n=32) received on a top of standard treatment the hemoperfusion (HP) procedure for 4 hours, for 2–3 days in a row, using a cytokine sorption column composed of mesoporous styrene-divinilbenzen copolymer matrix. Group 2 patients were not subjected to extracorporeal blood purification. All patients received IL-6 inhibitors at a baseline in accordance to the temporary guidelines. We evaluated factors of unfavorable outcomes by analyzing changes in biochemical markers of systemic inflammatory response and mortality rates in patients of both groups.Results. Initiation of HP later than 10 days from NCI onset (P < 0.001), length of stay in the ICU, extent of lung damage (P = 0.036) and the SOFA (Sequential Organ Failure Assessment) score (P = 0.009) were the most powerful predictors of unfavorable outcome. Levels of systemic inflammatory response markers (interleukin- 6, CRP, D-dimer) in both groups did not significantly affect the survival rates and length of hospital stay (P > 0.05). HP group demonstrated better survival (P < 0.05). Mean hospital stay was 31 and 27 days, ICU stay — 11 and 8 days for Groups 1 and 2, respectively (P < 0.05).Conclusion. Treatment of severe COVID-19 patients with HP using novel domestic hemosorbent composed of styrene-divinilbenzen copolymer matrix resulted in decrease in CRP levels on the first day after application and, with early onset, contributed to a significant increase in survival and decreased hospital and ICU stay. Additional studies are warranted to clarify the optimal timing of the initiation of HP in severe COVID-19 patients.
10 June 2021 in Kazan medical journal
Aim. To assess the effect of meglumine sodium succinate on the effectiveness of basic therapy in correcting gas exchange abnormalities in patients with severe COVID-19 infection complicated by bilateral community-acquired pneumonia. Methods. The analysis of the effectiveness of therapy of 12 patients with a diagnosis of New coronavirus infection COVID-19 (confirmed), severe form U07.1. Complication: bilateral multifocal pneumonia was carried out. The patients were divided into two groups: 7 received, as part of standard therapy, a solution of meglumine sodium succinate in a daily dose of 5 ml/kg during stay in the intensive care unit; 5 patients received a similar volume of Ringer's solution and formed the control group. In the arterial and venous blood of all patients, the indicators of acid-base state and water-electrolyte balance, glycemia and lactatemia were measured at several stages: (1) at admission to the intensive care unit, (2) 24 hours after the start of intensive therapy, (3) after 812 hours, (4) after 24 hours. On the 28th day of observation, mortality, the duration of treatment in the intensive care unit and the incidence of thrombotic complications in the groups were assessed. The Friedman nonparametric hypothesis test was used to assess intragroup dynamics, and the nonparametric Mannhitney U test for intergroup comparisons. Results. In the group of patients who received meglumine sodium succinate, there was a significant decrease in the incidence of thromboembolic events during 28 days of treatment: myocardial ischemia event rate ratio from 0.89 [95% confidence interval (CI) 0.191.16] in the control group to 0.55 (95% CI 0.060.81) in the study group at p=0.043; pulmonary embolism event from 0.50 (95% CI 01.0) in the control group to 0.28 (95% CI 01.0) in the study group at p=0.041. There was also a decrease in the duration of intensive care unit length of stay to 6.11.1 days in the study group versus 8.91.3 days in the control group. Conclusion. Compared with standard infusion therapy, the use of meglumine sodium succinate leads to a faster normalization of ventilation-perfusion ratios in patients with severe coronavirus infection.
1 January 2022 in Russian Journal of Anesthesiology and Reanimatology
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) на выраженность эндотелиальной дисфункции у пациентов с тяжелой формой новой коронавирусной инфекции (COVID-19). МАТЕРИАЛ И МЕТОДЫ В исследование включены 53 пациента с тяжелой формой COVID-19, осложненной двусторонней полисегментарной пневмонией. Все пациенты исходно методом конвертов рандомизированы на две группы. В комплекс терапии пациентов группы исследования (n=27) включена ежедневная инфузия сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) — препарата реамберин в дозе 10 мл на 1 кг массы тела в течение 4 ч однократно с курсом до 11 дней (или на протяжении времени пребывания в отделении реанимации). Пациенты контрольной группы (n=26) получали в качестве инфузионной среды раствор Рингера в том же объеме. В динамике исследовали содержание эндотелиоцитов, гомоцистеина, тромбоцитов и показатели коагулограммы. РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Оценка выраженности эндотелиальной дисфункции показала, что у пациентов, получавших реамберин, определялось более выраженное (p<0,05) снижение исходно повышенного уровня эндотелиоцитов и концентрации гомоцистеина на всех этапах исследования. Существенные межгрупповые различия проявлялись начиная со вторых суток наблюдения. Инфузионная коррекция выраженности эндотелиальной дисфункции приводила к снижению частоты тромботических осложнений, вероятности перевода на инвазивную искусственную вентиляцию легких и летальности по сравнению с традиционным подходом. ЗАКЛЮЧЕНИЕ Применение сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) в комплексной терапии тяжелых форм новой коронавирусной инфекции оправдано более значительной и стойкой коррекцией исходно выраженной дисфункции эндотелия, способствующей снижению количества тромботических осложнений, переводов на инвазивную искусственную вентиляцию легких и летальности.
31 July 2025 in Annals of Critical Care
СЕС.м. Ефремов С.м. Ефремов
С.м. Ефремов С.м. Ефремов
ИЛИлья Наумович Лейдерман
+49
INTRODUCTION: Nutritional support is an integral part of the treatment process in the intensive care unit (ICU). Patients in critical care receive some methods of enteral or parenteral nutrition based on often conflicting guidelines and controversial strategies. OBJECTIVE: To identify key trends in the use of metabolic control and nutritional support technologies in ICUs of different profiles. MATERIALS AND METHODS: The project of this screening study was developed by members of the FAR RF Committee on Nutritional Support and Metabolic Control. The design trial was simple random sampling. The study included 569 ICU patients. Results. The mean age of the patients was 59.22 ± 17.93 years. APACHE II scale — 1.3 ± 3.9 points, according to SOFA scale — 3.7 ± 1.5 points. 56 % of patients underwent surgical interventions, 45 % were on mechanical ventilation, 28-day mortality — 24 %. In 25 % of oncological patients the total protein was below 50 g\l. Serum albumin level was statistically significantly lower (p = 0,013) in the group of patients with acute cerebral insufficiency (ACI) in comparison with oncosurgical patients. In 25 % of multidisciplinary ICU patients albumin concentration was below 25 g/l. Energy requirement was determined empiricaly in 44 % of oncologic patients, in 50 % of patients with ACI the method of c equations was used, and indirect calorimetry was used in all groups in no more than 1 % of cases. Protein requirements were empirically determined in 20 % of cases in all groups. 35 % of physicians estimated the protein requirement based on the value of 1.2–1.5 g/kg/day. Enteral tube feeding was more frequently used by 70 % of ACI patients and 29 % in the oncology group. In contrast, 29 % of oncologic patients received parenteral nutrition. Only 5 % of patients with ACI required parenteral nutrition. CONCLUSIONS: The majority of ICU patients are characterized by such manifestations of protein-energy deficiency as hypoproteinemia, hypoalbuminemia, hypotransferrinemia. Enteral tube feeding is the prevailing method of nutritional support in ICU. The main problem identified in the course of screening should be considered the very rare use of metabolic monitoring technologies and the lack of a personalized approach to the selection of the nutritional support program.
31 January 2025 in General Reanimatology
Prevention of brain injury during carotid endarterectomy (CEA) remains a significant challenge. Moderate controlled systemic hypothermia may serve as a potential neuroprotective measure during these procedures.Aim of the study. To investigate the neuroprotective effects of moderate systemic hypothermia during CEA.Materials and methods. Fifty-nine patients undergoing CEA under combined anesthesia were included. Patients were divided into two groups: the hypothermia group (N=33) and the normothermia control group (N=26). Both groups received standard measures to prevent cerebral ischemia. The hypothermia group received additional moderate systemic hypothermia aimed at a temperature range of 34–35°C. Cognitive function was assessed preoperatively and at 2, 5, and 30 days postoperatively using neurocognitive tests. Statistical analysis was performed with IBM SPSS Statistics.Results. The incidence of cognitive impairment was 21.1% in the hypothermia group and 26.9% in the normothermia group. Postoperative cognitive impairment was more common in the normothermia group: 15.38% on day 5 and 11.5% on day 30 postoperatively compared to 12.1% and 6.1% in the hypothermia group (P<0.05).Conclusion. This study demonstrated the neuroprotective effects of hypothermia, manifested by a reduced severity of cognitive impairment in the hypothermia group. Further research is needed to identify high-risk patients who would benefit most from this neuroprotective strategy and to optimize hypothermia protocols.
1 January 2018 in Citologiâ
S4State Budgetary Institution of Health Nizhny Novgorod region «City clinical hospital N 40»
State Budgetary Institution of Health Nizhny Novgorod region «City clinical hospital N 40»
+2